The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses an international survey which aimed to elucidate the therapy related factors influencing treatment preferences of physicians when treating patients with relapsed/refractory (R/R) follicular lymphoma (FL). When selecting second- and third-line therapies, the progression-free survival (PFS) associated with a therapeutic option was the most influential factor in the decision-making of physicians. Physicians selected treatment for patients based on the nature of their disease and were willing to take more risks at advanced stages of disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AstraZeneca, AbbVie, Kite – A Gilead Company, Janssen Pharmaceuticals Inc., Novartis
Research Funding: AstraZeneca, Janssen Pharmaceuticals Inc.
Speakers Bureau: AbbVie, A Gilead Company, Janssen Pharmaceuticals Inc., Bristol Myers Squibb
